NorthRock Partners LLC Makes New Investment in Insulet Co. (NASDAQ:PODD)

NorthRock Partners LLC bought a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,021 shares of the medical instruments supplier's stock, valued at approximately $267,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PODD. Integral Health Asset Management LLC acquired a new stake in shares of Insulet in the fourth quarter valued at approximately $5,221,000. Investment Management Corp of Ontario boosted its stake in Insulet by 36.5% during the fourth quarter. Investment Management Corp of Ontario now owns 3,099 shares of the medical instruments supplier's stock valued at $809,000 after buying an additional 828 shares in the last quarter. Iron Triangle Partners LP grew its holdings in Insulet by 40.0% during the fourth quarter. Iron Triangle Partners LP now owns 154,014 shares of the medical instruments supplier's stock worth $40,208,000 after acquiring an additional 44,014 shares during the period. Janus Henderson Group PLC lifted its position in shares of Insulet by 7.0% during the 4th quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier's stock valued at $2,049,000 after acquiring an additional 511 shares during the last quarter. Finally, Gotham Asset Management LLC boosted its holdings in shares of Insulet by 57.2% in the fourth quarter. Gotham Asset Management LLC now owns 6,827 shares of the medical instruments supplier's stock worth $1,782,000 after buying an additional 2,485 shares during the period.

Analysts Set New Price Targets

Several equities analysts have commented on PODD shares. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Stifel Nicolaus raised their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Citigroup reiterated a "buy" rating and set a $380.00 target price (up from $320.00) on shares of Insulet in a research note on Thursday. Finally, Royal Bank of Canada began coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $308.00.

Insider Activity at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of NASDAQ:PODD traded down $0.05 on Friday, reaching $320.95. 279,853 shares of the company's stock were exchanged, compared to its average volume of 707,325. The company has a fifty day moving average of $269.92 and a 200-day moving average of $268.95. The company has a market capitalization of $22.59 billion, a price-to-earnings ratio of 55.53, a PEG ratio of 3.62 and a beta of 1.26. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $170.67 and a twelve month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The business's revenue for the quarter was up 28.8% compared to the same quarter last year. On average, research analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.